Does the media prefer GMAB or TVTX?

In the previous week, Travere Therapeutics had 8 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Travere Therapeutics and 5 mentions for Genmab A/S. Travere Therapeutics' average media sentiment score of 0.54 beat Genmab A/S's score of 0.31 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or TVTX?

In the previous week, Travere Therapeutics had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 13 mentions for Travere Therapeutics and 11 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.20 beat Travere Therapeutics' score of 0.54 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or TVTX?

In the previous week, Travere Therapeutics had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Travere Therapeutics and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.12 beat Travere Therapeutics' score of 0.54 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or AXSM?

In the previous week, Axsome Therapeutics had 12 more articles in the media than Travere Therapeutics. MarketBeat recorded 25 mentions for Axsome Therapeutics and 13 mentions for Travere Therapeutics. Axsome Therapeutics' average media sentiment score of 0.79 beat Travere Therapeutics' score of 0.54 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 13 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or TVTX?

In the previous week, Travere Therapeutics had 7 more articles in the media than Elanco Animal Health. MarketBeat recorded 13 mentions for Travere Therapeutics and 6 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.05 beat Travere Therapeutics' score of 0.54 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Travere Therapeutics (TVTX) Competitors

$54.14 +0.76 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$55.25 +1.11 (+2.05%)

As of 06:54 PM Eastern

Compare

TVTX vs. GMAB, BBIO, ASND, AXSM, and ELAN

Should you buy Travere Therapeutics stock or one of its competitors? MarketBeat compares Travere Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Travere Therapeutics include Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Travere Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Travere Therapeutics had 8 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Travere Therapeutics and 5 mentions for Genmab A/S. Travere Therapeutics' average media sentiment score of 0.54 beat Genmab A/S's score of 0.31 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.26	$963M	$1.32	19.23
Travere Therapeutics	$490.73M	10.26	-$25.55M	-$0.23	N/A

Genmab A/S has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Genmab A/S presently has a consensus target price of $37.93, suggesting a potential upside of 49.38%. Travere Therapeutics has a consensus target price of $50.83, suggesting a potential downside of 6.11%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Genmab A/S has a net margin of 21.05% compared to Travere Therapeutics' net margin of -4.00%. Genmab A/S's return on equity of 15.34% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

Genmab A/S beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Travere Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Travere Therapeutics has a net margin of -4.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

BridgeBio Pharma currently has a consensus price target of $91.05, indicating a potential upside of 35.11%. Travere Therapeutics has a consensus price target of $50.83, indicating a potential downside of 6.11%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe BridgeBio Pharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Travere Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.29	-$724.93M	-$3.74	N/A
Travere Therapeutics	$490.73M	10.26	-$25.55M	-$0.23	N/A

In the previous week, Travere Therapeutics had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 13 mentions for Travere Therapeutics and 11 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.20 beat Travere Therapeutics' score of 0.54 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats Travere Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Travere Therapeutics had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Travere Therapeutics and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.12 beat Travere Therapeutics' score of 0.54 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.70	-$258M	$8.67	26.66
Travere Therapeutics	$490.73M	10.26	-$25.55M	-$0.23	N/A

Ascendis Pharma A/S presently has a consensus target price of $295.39, indicating a potential upside of 27.79%. Travere Therapeutics has a consensus target price of $50.83, indicating a potential downside of 6.11%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Travere Therapeutics' net margin of -4.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

Ascendis Pharma A/S beats Travere Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Travere Therapeutics compare to Axsome Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Travere Therapeutics has a net margin of -4.00% compared to Axsome Therapeutics' net margin of -26.59%. Travere Therapeutics' return on equity of -26.16% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Travere Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.26	-$25.55M	-$0.23	N/A
Axsome Therapeutics	$638.50M	20.32	-$183.17M	-$3.73	N/A

Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 12 more articles in the media than Travere Therapeutics. MarketBeat recorded 25 mentions for Axsome Therapeutics and 13 mentions for Travere Therapeutics. Axsome Therapeutics' average media sentiment score of 0.79 beat Travere Therapeutics' score of 0.54 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	13 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics currently has a consensus price target of $50.83, suggesting a potential downside of 6.11%. Axsome Therapeutics has a consensus price target of $258.95, suggesting a potential upside of 2.69%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Axsome Therapeutics beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Travere Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Travere Therapeutics had 7 more articles in the media than Elanco Animal Health. MarketBeat recorded 13 mentions for Travere Therapeutics and 6 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.05 beat Travere Therapeutics' score of 0.54 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health currently has a consensus target price of $28.20, suggesting a potential upside of 20.75%. Travere Therapeutics has a consensus target price of $50.83, suggesting a potential downside of 6.11%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Elanco Animal Health is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Travere Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Travere Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.47	-$232M	-$0.50	N/A
Travere Therapeutics	$490.73M	10.26	-$25.55M	-$0.23	N/A

Travere Therapeutics has a net margin of -4.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

Elanco Animal Health beats Travere Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVTX vs. The Competition

Export

Metric	Travere Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.96B	$3.40B	$6.42B	$12.06B
Dividend Yield	N/A	2.26%	2.67%	5.64%
P/E Ratio	-235.38	19.72	24.58	24.08
Price / Sales	10.26	181.62	491.62	87.72
Price / Cash	147.40	125.07	44.13	56.69
Price / Book	42.30	8.18	10.63	6.63
Net Income	-$25.55M	$23.94M	$3.57B	$337.89M
7 Day Performance	15.83%	4.06%	1.42%	1.65%
1 Month Performance	27.12%	1.69%	2.01%	3.10%
1 Year Performance	284.24%	51.98%	27.77%	29.69%

Travere Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVTX Travere Therapeutics	1.2416 of 5 stars	$54.14 +1.4%	$50.83 -6.1%	+263.6%	$4.96B	$490.73M	N/A	460	Analyst Forecast Insider Trade
GMAB Genmab A/S	4.3703 of 5 stars	$24.72 -1.7%	$37.93 +53.5%	+8.2%	$15.41B	$3.90B	18.72	3,029
BBIO BridgeBio Pharma	3.6047 of 5 stars	$67.45 -0.2%	$89.59 +32.8%	+62.0%	$13.21B	$579.96M	N/A	400	Positive News Analyst Forecast Insider Trade
ASND Ascendis Pharma A/S	4.515 of 5 stars	$205.15 -2.5%	$295.39 +44.0%	+30.1%	$12.80B	$865.78M	23.68	1,189	Positive News
AXSM Axsome Therapeutics	1.7334 of 5 stars	$235.90 +1.5%	$251.26 +6.5%	+147.7%	$12.16B	$708.24M	N/A	380	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVTX) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Competitors

TVTX vs. GMAB, BBIO, ASND, AXSM, and ELAN

How does Travere Therapeutics compare to Genmab A/S?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Travere Therapeutics compare to Axsome Therapeutics?

Summary

How does Travere Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Competitors

TVTX vs. GMAB, BBIO, ASND, AXSM, and ELAN

How does Travere Therapeutics compare to Genmab A/S?

Does the media prefer GMAB or TVTX?

Which has better valuation and earnings, GMAB or TVTX?

Which has more volatility & risk, GMAB or TVTX?

Do insiders and institutionals have more ownership in GMAB or TVTX?

Do analysts prefer GMAB or TVTX?

Is GMAB or TVTX more profitable?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Which has more risk and volatility, BBIO or TVTX?

Is BBIO or TVTX more profitable?

Do analysts recommend BBIO or TVTX?

Which has preferable valuation & earnings, BBIO or TVTX?

Does the media prefer BBIO or TVTX?

Do insiders and institutionals hold more shares of BBIO or TVTX?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Does the media favor ASND or TVTX?

Which has stronger valuation & earnings, ASND or TVTX?

Do analysts recommend ASND or TVTX?

Which has more risk and volatility, ASND or TVTX?

Is ASND or TVTX more profitable?

Summary

How does Travere Therapeutics compare to Axsome Therapeutics?

Do institutionals and insiders hold more shares of TVTX or AXSM?

Is TVTX or AXSM more profitable?

Which has better valuation & earnings, TVTX or AXSM?

Which has more risk & volatility, TVTX or AXSM?

Does the media prefer TVTX or AXSM?

Do analysts prefer TVTX or AXSM?

Summary

How does Travere Therapeutics compare to Elanco Animal Health?

Do insiders & institutionals hold more shares of ELAN or TVTX?

Does the media favor ELAN or TVTX?

Do analysts prefer ELAN or TVTX?

Which has more volatility and risk, ELAN or TVTX?

Which has better valuation and earnings, ELAN or TVTX?

Is ELAN or TVTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools